AXIM Biotechnologies Partners With VisionPlus for South Korean Market Entry of TearScan Diagnostic Tests

AXIM Biotechnologies has entered into an exclusive distribution agreement with VisionPlus Corp. to market and distribute its TearScan diagnostic tests throughout South Korea. The partnership will introduce AXIM's TearScan Lactoferrin Test for detecting aqueous-deficient dry eye and TearScan IgE Test for ocular allergy to the Korean market, supported by the I-Peak digital reader system.

Under the agreement terms, VisionPlus receives exclusive distribution rights for both diagnostic tests across South Korea. The companies will collaborate on Korean MFDS registration submissions for both assays, with VisionPlus leading local compliance, regulatory coordination, and commercialization through its established network of ophthalmology clinics, hospitals, and specialty Dry Eye Centers. The initial agreement term spans one year with automatic one-year renewals for an additional four years, contingent upon meeting annual sales milestones.

Catalina Valencia, President of AXIM Biotechnologies, emphasized the strategic importance of this partnership, stating that VisionPlus brings exceptional clinical insight and national reach to introduce the TearScan platform to South Korea. The collaboration aims to bring quantitative tear diagnostics directly to clinicians, improving diagnostic precision and enabling more personalized care for patients suffering from dry eye disease and ocular allergy.

Jerry Park, President of VisionPlus Corp., highlighted the growing need for advanced dry eye diagnostics in South Korea, noting that years ago his company recognized the global rise in digital device use and worsening environmental conditions would lead to a dry eye disease epidemic. VisionPlus established dedicated Dry Eye Clinics across Korea in anticipation of this need, and AXIM's TearScan tests will complete their vision of creating a comprehensive diagnostic and treatment ecosystem for Dry Eye Disease and related conditions.

The TearScan diagnostic portfolio represents a significant advancement in ocular healthcare, providing quantitative, point-of-care tear biomarker analysis in minutes using minimal tear samples. The system's reader delivers precise measurements that help clinicians differentiate between aqueous-deficient dry eye, evaporative dry eye, and allergic conjunctivitis—a crucial distinction for selecting effective therapy and monitoring patient progress. For more information about AXIM's technology, visit https://www.aximbiotech.com.

This market entry comes at a critical time as South Korea faces increasing rates of ocular conditions driven by high digital device usage and environmental factors. The partnership positions both companies to address a substantial healthcare need while establishing AXIM's presence in the Asian market through VisionPlus's established distribution channels and clinical relationships.